Skip to main content

Advertisement

SpringerLink
Log in

Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor?

  • Original Article – Cancer Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Introduction

Non-adherence to anti-hormonal therapy is a major problem in gynecologic oncology. Reasons reported are side effects and lack of support. The aim of our study was an analysis of influence of experiences of patients with endocrine therapy and communication and information on this topic and their influence on adherence.

Methods

We developed a structured questionnaire which was tested in a pilot version and then programmed as online questionnaire and presented to patient members of self-help and breast cancer organizations.

Results

Patients only had received scarce information on endocrine therapy. Only 12.8 % stated that their questions were answered in detail, 43.2 % got no answers or only non-detailed answers. 76 % had side effects limiting functions of daily life. 60 % of physicians did not react on these side effects. There is a significant correlation between number and intensity of side effects and non-adherence or disruption of therapy (p = 0.029 and p < 0.01, respectively). Women who reported having received detailed answers to their questions also reported better adherence (p = 0.014).

Conclusion

In order to improve adherence, detailed information on side effects and answers in case of symptoms are most important. Physicians should not rely on presenting written information but should mainly engage in direct communication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bell RJ, Fradkin P, Schwarz M, Davis SR (2013) Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause 20(1):15–21

    Article  PubMed  Google Scholar 

  • Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71(1–2):1–9

    CAS  PubMed  Google Scholar 

  • Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23:882–890

    Article  CAS  PubMed  Google Scholar 

  • Güth U, Huang DJ, Schötzau A, Zanetti-Dällenbach R, Holzgreve W, Bitzer J, Wight E (2008) Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 99(3):428–433

    Article  PubMed Central  PubMed  Google Scholar 

  • Güth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM (2012) Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 131(2):491–499

    Article  PubMed  Google Scholar 

  • Hadjy P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Kreienberg R (2013) The patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study in the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24:505–512

    Google Scholar 

  • Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128

    Article  PubMed Central  PubMed  Google Scholar 

  • Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) ATAC Trialists’ group: results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvanttreatment for breast cancer. Lancet 365:60–62

    Article  CAS  PubMed  Google Scholar 

  • Huiart L, Dell’Aniello S, Suissa S (2011) Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer 104(10):1558–1563

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Land SR, Cronin WM, Wickerham DL, Costantino JP, Christian NJ, Klein WM, Ganz PA (2011) Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res (Phila) 4(9):1393–1400

    Article  CAS  Google Scholar 

  • Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215–220

    Article  PubMed  Google Scholar 

  • Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137:829–836

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2):681–689

    Article  CAS  PubMed  Google Scholar 

  • Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606

    Article  CAS  PubMed  Google Scholar 

  • Thurlimann B, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A (2005) Breast international group (BIG) 1–98 collaborative group: a comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757

    Article  PubMed  Google Scholar 

  • van de Water W, Bastiaannet E, Hille ET, Meershoek-Klein Kranenbarg EM, Putter H, Seynaeve CM, Paridaens R, de Craen AJ, Westendorp RG, Liefers GJ, van de Velde CJ (2012) Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. Oncologist 17(1):55–63

    Article  PubMed Central  PubMed  Google Scholar 

  • van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122(3):843–851

    Article  PubMed  Google Scholar 

  • Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Bergkvist L, Lambe M (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat 133(1):367–373

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Working Group Integrative Oncology, Dr. Senckenberg Chronomedical Institute, J. W. Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany

    P. Wuensch & J. Huebner

  2. BRCA-Network, Haus der Krebsselbsthilfe Bonn, Bonn, Germany

    A. Hahne

  3. Brustkrebs Deutschland e.V., Munich, Germany

    R. Haidinger

  4. Frauenselbsthilfe nach Krebs, Haus der Krebsselbsthilfe Bonn, Bonn, Germany

    K. Meißler

  5. Kombra, Hamburg, Germany

    B. Tenter

  6. Clinic Herzoghoehe Bayreuth, Bayreuth, Germany

    C. Stoll

  7. Division for Psychooncology, J. W. Goethe University, Frankfurt, Germany

    B. Senf

Authors
  1. P. Wuensch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Hahne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Haidinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Meißler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Tenter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Stoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Senf
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Huebner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Huebner.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 22 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wuensch, P., Hahne, A., Haidinger, R. et al. Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor?. J Cancer Res Clin Oncol 141, 55–60 (2015). https://doi.org/10.1007/s00432-014-1779-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-014-1779-z

Keywords

Search

Navigation